<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39418687</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.</ArticleTitle><Pagination><StartPage>126437</StartPage><MedlinePgn>126437</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126437</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01119-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Healthcare providers' (HCPs') beliefs and practices regarding vaccination influence vaccine acceptance in patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe HCPs' beliefs and practices regarding vaccines and perceptions of patient perspectives related to vaccine hesitancy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a non-interventional, cross-sectional, online survey administered to 1213 HCPs based in the United States from December 2021 through January 2022. HCPs provided responses regarding their demographic and professional characteristics, beliefs about vaccine safety and effectiveness, vaccination practices, and their views regarding patients' willingness to receive vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Study participants included doctors (55.4 %); physician assistants (11.2 %); pharmacists (11.7 %); nurse practitioners (11.1 %); and registered nurses (10.6 %) from across the United States (West, 35.6 %; Midwest, 27.0 %; South, 25.6 %; Northeast, 11.9 %). HCPs belonged to group practices or clinics (34.5 %), private practices (31.9 %), hospital-based practices (21.9 %), or pharmacies (11.7 %). Most HCPs strongly believed it was their duty to promote vaccination (78.1 %) and used in-person conversations to educate patients about vaccines (85.0 %); 95.1 % had been vaccinated against COVID-19. HCPs reported that 54.9 % of patients accept all vaccines without hesitation, 21.0 % accept all vaccines but hesitate, 16.8 % accept only select vaccines, and 7.2 % reject all vaccines. Reasons commonly cited by patients for being hesitant to accept vaccines or refusal included negative media (hesitancy: 64.6 %; refusal: 73.2 %), the influence of friends or family (hesitancy: 60.5 %; refusal: 68.7 %), distrust of the government (hesitancy: 45.8 %; refusal: 68.4 %), concerns over long-term side effects (hesitancy: 56.1 %; refusal: 68.3 %), and worries about vaccine-related autism or infertility (hesitancy: 49.7 %; refusal: 71.9 %). HCPs reported that the largest contributors to vaccine misinformation among patients were social media (91.0 %), celebrities/TV personalities (63.5 %), and mass media (61.1 %).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite most HCPs being active proponents of vaccination, misconceptions about vaccination and vaccine hesitancy persists. Consideration should be given to HCP training to support their efforts to promote vaccine acceptance.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eiden</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, NJ, USA. Electronic address: Amanda.Eiden@merck.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drakeley</LastName><ForeName>Sheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oracle Life Science, Oracle, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modi</LastName><ForeName>Kushal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Oracle Life Science, Oracle, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackie</LastName><ForeName>deMauri</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Oracle Life Science, Oracle, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatti</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiFranzo</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Merck &amp; Co., Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cross-sectional study</Keyword><Keyword MajorTopicYN="N">Health knowledge, attitudes, practice</Keyword><Keyword MajorTopicYN="N">Healthcare providers</Keyword><Keyword MajorTopicYN="N">Survey questionnaire</Keyword><Keyword MajorTopicYN="N">Vaccine hesitancy</Keyword></KeywordList><CoiStatement>Declaration of competing interest ALE, AB, AD are current employees of Merck Sharp &amp; Dohme LLC., a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA, and may hold equity interest in Merck &amp; Co., Inc., Rahway, NJ, USA. KM and SD are current employees and dMM is a former employee of Oracle Life Sciences, Oracle Corporation (formerly known as Cerner Enziva), which received research funding from Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA to conduct and report on the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39418687</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126437</ArticleId><ArticleId IdType="pii">S0264-410X(24)01119-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>